TX-SONAR
10.6.2024 15:01:28 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced the expansion of its collaboration with Amazon Web Services (AWS) to help enterprises achieve high-quality code that is clean. SonarCloud, Sonar’s SaaS offering, will be available as an integration with Amazon CodeCatalyst, a unified software development service. Additionally, SonarCloud is now certified by the AWS Foundational Technical Review (FTR) – a set of guidelines to reduce risks around security, reliability, and operational excellence, as defined by the AWS Well-Architected Framework.
“With SonarCloud we enabled our engineering teams to drive consistent code quality and standards across the whole organization. The easy integration into our development toolchain and the simple UI allow us to scale fast and without any issues. The wide adoption and the excellent customer support help you overcome any difficulties,” said Andre Ostermeier, Lead Solutions Architect at Relayr. “Besides that, SonarCloud is an excellent tool to drive Engineering KPIs and should not be underestimated by IT leaders.”
SonarCloud and Amazon CodeCatalyst: Improving Development Processes
Amazon CodeCatalyst features blueprint capabilities that allow customers to automatically set up everything they need to start a new software development project, including continuous integration and delivery (CI/CD) pipelines, deployable code, issue tracking, and fully configured AWS services.
“Customers building apps need to release code early and often, and with solid DevOps practices and tools,” said Nicolas Pujol, ISV Partner Management Leader in EMEA, AWS. “Sonar has done a great job giving developers and DevOps leaders solutions to be more productive, and we’re excited to collaborate to make these tools available to AWS customers.”
Amazon CodeCatalyst paired with Sonar’s unique Clean as You Code approach, delivered through SonarCloud, empowers developers to spend more time writing innovative code and less time managing local development environments. With SonarCloud integrated into Amazon CodeCatalyst CI/CD workflows, development teams can more easily ensure that only clean code will be added to their code base, improving the overall quality of the code written.
Sonar Puts Customer Experience First
Sonar achieved the AWS Foundational Technical Review (FTR) certification by demonstrating that SonarCloud meets best practices critical for a customer’s success. SonarCloud allows for shared expectations across teams rooted in clean code practices, automates code quality checks, and provides extensive feedback for issue resolution.
Sonar’s Clean as You Code Approach
The Clean as You Code approach enables developers and organizations to improve development velocity, code quality, and code security. This simple yet powerful methodology progressively improves the overall quality of the entire codebase as the code is written, with minimal cost and effort. Clean as You Code puts developers in the driver's seat where they take full ownership of the quality of the code they write.
“An increasing number of developers are writing code and building apps in the cloud. We created SonarCloud to provide these developers an easy way to achieve a state of Clean Code, designing a tool that seamlessly integrates with DevOps platforms,” said Fabrice Bellingard, VP of Products at Sonar. “Our growing collaboration with AWS will help more cloud-based development teams create high-quality code with our unique Clean as You Code methodology.”
Today, SonarCloud has over 100,000 active users. The solution has helped a wide range of organizations clean over 2.5 billion lines of code. SonarCloud is free to use on open-source projects. To learn more about SonarCloud, visit here.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610167595/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom